Institutional Position
The Drugs Controller General of India, commonly known as DCGI, is the central regulatory authority responsible for the approval and regulation of drugs, vaccines, certain medical devices and clinical trials in India.
The DCGI heads the Central Drugs Standard Control Organisation, known as CDSCO. It functions under the Directorate General of Health Services in the Ministry of Health and Family Welfare.
The DCGI is not a separate constitutional or statutory body. It is an executive regulatory office within the Union health administration.
CDSCO operates through its headquarters in New Delhi, along with zonal offices, sub-zonal offices, port offices and central drug-testing laboratories across the country.
Legal and Regulatory Framework
Drug regulation in India is primarily governed by the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945.
Other important rules include:
- Medical Devices Rules, 2017
- New Drugs and Clinical Trials Rules, 2019
- Cosmetics Rules, 2020
The New Drugs and Clinical Trials Rules regulate clinical trials, approval of new drugs, bioavailability and bioequivalence studies, functioning of ethics committees and compensation for trial-related injury.
Drug regulation in India is divided between the Union Government and state governments.
The Central Government is mainly responsible for:
- approval of new drugs and vaccines;
- permission for clinical trials;
- regulation of imported drugs;
- regulation of specified medical devices;
- establishment of national drug standards;
- coordination among state drug regulators.
State drug-control authorities are mainly responsible for issuing manufacturing and sale licences for many pharmaceutical products and enforcing drug-quality standards within their jurisdictions.
Major Functions
The DCGI evaluates applications for the introduction of new medicines, vaccines and specified medical devices in India.
Its major functions include:
- approving new drugs and vaccines;
- granting permission for clinical trials;
- regulating the import of drugs and cosmetics;
- approving specified medical devices;
- supervising bioavailability and bioequivalence studies;
- establishing standards for drug quality;
- monitoring adverse drug reactions;
- coordinating with state drug-control authorities.
The DCGI also regulates important categories such as vaccines, sera, blood products and intravenous fluids.
Before approving a new drug, the regulator examines:
- laboratory and animal-study data;
- clinical trial results;
- manufacturing quality;
- safety and effectiveness;
- stability and storage requirements;
- proposed dosage and labelling;
- potential risks and therapeutic benefits.
Expert committees consisting of doctors, scientists and pharmacology specialists may be consulted during the approval process.
Approval by the DCGI does not automatically mean that a medicine or vaccine will be included in a government health programme. Such inclusion depends on additional factors such as disease burden, cost-effectiveness, affordability, availability and public-health priorities.
Drug Approval and Safety Monitoring
Regulation continues even after a drug enters the market. This process is known as post-marketing surveillance or pharmacovigilance.
Manufacturers may be required to report:
- serious adverse events;
- unexpected side effects;
- product-quality defects;
- manufacturing changes;
- new safety information;
- results of post-marketing studies.
If major safety or quality concerns arise, the regulator may:
- require changes in product labelling;
- restrict the use of the drug;
- order additional studies;
- suspend or cancel approval;
- recall affected batches;
- prohibit import, manufacture or sale.
Drug-testing laboratories support this system by testing samples for identity, purity, strength, sterility and compliance with prescribed standards.
This process is necessary because some rare side effects or quality problems may become visible only after a drug is used by a large population.
Challenges and Reforms
India has one of the world’s largest pharmaceutical industries, with thousands of manufacturers and complex supply chains. This creates significant regulatory challenges.
Major concerns include:
- uneven enforcement capacity across states;
- circulation of substandard or falsified medicines;
- shortage of trained drug inspectors;
- delays in laboratory testing;
- weak coordination between central and state authorities;
- limited transparency in some approval decisions;
- inadequate post-marketing surveillance;
- rapid growth of biological products and medical devices.
Important reforms include:
- strengthening CDSCO and state drug-control departments;
- increasing the number of trained inspectors;
- modernising drug-testing laboratories;
- creating integrated digital regulatory databases;
- improving adverse-event reporting;
- conducting risk-based inspections;
- increasing transparency in approval decisions;
- ensuring uniform enforcement across states.
A strong regulatory system must balance quick access to essential medicines with strict protection of public health.
Conclusion
The Drugs Controller General of India plays a central role in ensuring the quality, safety and effectiveness of medicines and vaccines in the country. Its performance directly affects public health, clinical research, pharmaceutical manufacturing and public confidence in the healthcare system.
